Recruiting
Phase 2
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
About this study
This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.
- Condition
- Metastatic Colorectal Cancer
- Tested
- SSGJ-707, Bevacizumab, Oxaliplatin, Capecitabine, Calcium Folinate, 5-fluorouracil
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Who can join
- Age
- 18 to 75 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 8
- Minimum age: 18 years
- Maximum age: 75 years
- Study condition: Metastatic Colorectal Cancer
- Males and/or females over age 18
- Histologically and/or cytologically documented metastatic colorectal cancer confirmed .
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Expected survival \>=12 weeks.
- Signed informed consent form.
Exclusion 5
- Known uncontrolled or symptomatic central nervous system metastatic disease.
- Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \>1 (National Cancer Institute Common terminology Criteria \[NCI CTCAE\] v.5.0).
- Inadequate organ or bone marrow function.
- Pregnant or breast-feeding woman.
- Known allergies, hypersensitivity, or intolerance to SSGJ-707 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Where
1 site, 1 recruiting
Liu Tianshu
Shanghai, Shanghai Municipality, China
Potential match only. Final eligibility is determined by the study team.